1. Uncategorized

Investigational New Drug CDMO Market Growth Status, Strategies, Key Factors, Comprehensive Analysis, Competitive Landscape And Forecast

Investigational New Drug CDMO Industry Overview

The global investigational new drug CDMO market size was valued at USD 4.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.9% from 2021 to 2028.

The market growth can be attributed to factors such as the increasing outsourcing services by pharmaceutical companies, rising R&D investments, and stringent regulations for conducting clinical studies. The FDA’s role in the development of a novel drug begins when the drug’s sponsor decides to test the new molecule’s diagnostic or therapeutic potential in humans after screening it for pharmacological activity and acute toxicity potential in animals. The molecule then changes its legal position under the Federal Food, Drug, and Cosmetic Act, becoming a new drug subject to the drug regulatory system’s specific requirements.

Gather more insights about the market drivers, restrains and growth of the Global Investigational New Drug CDMO Market

According to the post-pandemic pharmaceutical landscape, the industry would see a rise in innovation, with cancer and rare diseases expected to benefit the most. Due to the recent surge in investigational new drug (IND) applications, contract services are predicted to grow substantially, with an estimated 75 annual FDA approvals expected by 2025. From April 2020 to June 2020, the FDA received 3,806 IND applications, more than in the preceding eight years combined (3,576 in 2012-2019).

Besides, the FDA’s expectations for new treatment drug development initiatives in the fight against COVID-19 are underlined in these two guidances, “COVID-19 Public Health Emergency: General Considerations for Pre-IND Meetings Requests for COVID-19 Related Drugs and Biological Products” and “COVID-19: Developing Drugs and Biological Products for Treatment of Prevention”.

According to this Pre-IND Guidance, all COVID-19 drug development interactions should be initiated through IND meeting requests, which were given to provide broad considerations to assist sponsors in developing Pre-IND meeting requests for COVID-19-related drugs. The FDA recommends that drug development applications be submitted through the Pre-IND programs rather than a pre-Emergency Use Authorization in order to improve the quality and content of IND submissions and streamline prospective sponsor bids.

The review and approval processes for IND applications and NDAs are continually evolving, thus influencing approval trends. In mid-2018, FDA Commissioner Scott Gottlieb declared plans to upgrade the agency’s office of drug review, and the agency issued draft guidance documents on the way the FDA would include patient input in regulatory decision-making. In reality, when it comes to regulatory approvals, the FDA has to take real-world evidence from off-label drug use into account. When evaluating drugs for approval, the FDA and other regulatory agencies take patient-reported outcomes into consideration.

Browse through Grand View Research’s Medical Devices Industry Research Reports.

  • Cosmetics Market – The global cosmetics market size was valued at USD 254.08 billion in 2021 and is anticipated to register a CAGR of 5.3% from 2022 to 2028. The extensive growth in the acceptance of skincare and personal care products coupled with the rise in the aging population across the globe is one of the major factors that propel the market growth during the forecast period.
  • Pharmaceutical Logistics Market – The global pharmaceutical logistics market size was valued at USD 78.5 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2022 to 2030. The short-term impact of the COVID-19 pandemic on the market is a crucial factor for the fast-paced growth of pharmaceutical logistics.

Investigational New Drug CDMO Market Segmentation

Grand View Research has segmented the global investigational new drug CDMO market based on product, service, end user, and region:

IND CDMO Product Outlook (Revenue, USD Million, 2016 – 2028)

  • Small Molecule
  • Large Molecule

IND CDMO Service Outlook (Revenue, USD Million, 2016 – 2028)

  • Contract Development
    1. Small Molecule
      1. Bioanalysis and DMPK Studies
      2. Toxicology Testing
      3. Pathology and Safety Pharmacology Studies
      4. Drug Substance Synthetic Route Development
      5. Drug Substance Process Development
      6. Form Selection Crystallization Process Development
      7. Scale-up of Drug Substance
      8. Preformulation
      9. Preclinical Formulation Selection
      10. First In Man Formulation/ Process Development
      11. Analytical Method Development / Validation
      12. Release Testing of Drug Substance and Drug Product
      13. Work Up Purification Steps
      14. Telescoping & Process Refining
      15. Initial Optimization
      16. Formal Stability of Drug Substance and Drug Product
    2. Large Molecule
      1. Cell Line Development
      2. Process Development
        1. Upstream
          1. Microbial
          2. Mammalian
          3. Others
        2. Downstream
          1. Mabs
          2. Recombinant Proteins
          3. Others
  • Contract Manufacturing
    1. Small Molecule
      1. Oral Solids
      2. Liquid and Semi-solids
      3. Injectables
      4. Others
    2. Large Molecule
      1. MABs
      2. Recombinant Proteins
      3. Others

IND CDMO End-user Outlook (Revenue, USD Million, 2016 – 2028)

  • Pharmaceutical Companies
  • Biotech Companies
  • Others (Government, Research Institutes, Academic Institutes, etc.) 

IND CDMO Regional Outlook (Revenue, USD Million, 2016 – 2028)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Market Share Insights

  • June 2021: Charles River Laboratories International, Inc. acquired Vigene Biosciences, Inc. The acquisition expanded its existing cell and gene therapy contract manufacturing capabilities and provided a complete gene-modified cell treatment solution in the U.S.
  • May 2020: The FDA has issued two new guideline documents for industry and investigators of COVID-19 drugs and biological products.

Key Companies profiled:

Some prominent players in the global investigational new drug CDMO market include

  • Covance Inc.
  • Charles River Laboratories Inc.
  • Cambrex Corporation
  • IQVIA Holdings Inc.
  • Syneos Health
  • Lonza
  • Catalent
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.

Order a free sample PDF of the Investigational New Drug CDMO Market Intelligence Study, published by Grand View Research. 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: [email protected]

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

Comments to: Investigational New Drug CDMO Market Growth Status, Strategies, Key Factors, Comprehensive Analysis, Competitive Landscape And Forecast